HomeHealthcare & Life SciencesPharmaceuticals Hepatic Encephalopathy Treatment Market

China Hepatic Encephalopathy Treatment Market Size & Outlook, 2026-2034


China Hepatic Encephalopathy Treatment Market Insights

  • As per Reed Intelligence insights, the China Hepatic Encephalopathy Treatment Market stood at USD 144.08 Million in 2025 and is anticipated to grow to USD 289.62 Million by 2034.
  • The China market is expected to advance at a CAGR of 8.02% from 2026 through 2034.
  • In 2025, Rifaximin accounted for the highest share of the Drug Class market size.
  • During the forecast period, L-ornithine L-aspartate is set to register the highest growth, making it the most lucrative Drug Class segment.

Other Key Findings


  • In 2025, China represented 5.81% of the overall global Hepatic Encephalopathy Treatment Market size.
  • United States is projected to lead the global Hepatic Encephalopathy Treatment Market size by 2034.
  • Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2034.
  • Japan is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 102.85 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 144.08 Million
Market Size In 2034 USD 289.62 Million
Largest segment Rifaximin
Units Revenue in USD Million
CAGR 8.02% (2026-2034)
Segmnetation Covered
Drug Class
  1. Rifaximin
  2. Lactulose
  3. L-ornithine L-aspartate
  4. Antibiotics
  5. Microbiome-based Therapies
Disease Type
  1. Overt Hepatic Encephalopathy
  2. Minimal Hepatic Encephalopathy
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports